Prestige Consumer Healthcare Inc. PBH R2KR3KPHARMA

Q: What is the current share price of Prestige Consumer Healthcare Inc. (PBH)?

As of 2026-09-07 16:24 PDT, Prestige Consumer Healthcare Inc. (PBH) trades at $52.26 on NYSE. Its 52-week range is $45.44 to $70.21.

Q: What is the market capitalisation of PBH?

Prestige Consumer Healthcare Inc. (PBH) has a market capitalisation of $2.48B on NYSE.

Q: What is the P/E ratio of PBH?

PBH trades at a trailing price-to-earnings (P/E) ratio of 14.64. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.38.

Q: What is the return on equity (ROE) of PBH?

PBH has a return on equity (ROE) of 9.12%. Its return on capital employed (ROCE) is 9.17%.

Q: Is PBH a good stock to buy?

This page provides a data-driven analysis of Prestige Consumer Healthcare Inc. (PBH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.prestigebrands.com

Company Profile ↓

$52.26

-21.33% 1Y

Mkt Cap$2.48B

P/E14.64

P/B1.38

52W High$70.21

52W Low$45.44

Book Value$39.89

EPS (TTM)$3.57

Company Overview

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 11.8% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 14.6, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 15.6%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of $1.09B (-4.3% YoY); net profit $190.30M.
Trailing 12 Months Year-on-year growth — revenue +6.5%, earnings -35.8%.
5-Year Trend Long-term compounding — revenue CAGR 8.6%, profit CAGR 11.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	8.56%
1 Year:	6.50%

Compounded Profit Growth

5 Years:	11.76%
1 Year:	-35.80%

Stock Price Performance

1 Year:	-21.33%
6 Months:	-22.22%
3 Months:	+10.77%
1 Month:	-3.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 28% of range

$45.44 $70.21

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)53.02 · Neutral

Price Performance

1M-3.99%

3M+10.77%

6M-22.22%

1Y-21.33%

Valuation vs Sector

P/E of 14.64 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 11.8% over 5 years.
Generates positive free cash flow.

CONS

Trading 25.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

14.64

Industry PE

25.17

Forward P/E

10.38

PEG Ratio

1.60

Book Value

$39.89

Price to Book

1.38

P/S

2.35

EV/EBITDA

13.54

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

8.56%

Profit 5Y

11.76%

Revenue (YoY)

6.50%

Earnings (YoY)

-35.80%

Profitability & Returns

ROCE

9.17%

ROE

9.12%

ROA

4.73%

Profit Margin

15.57%

Op Margin

24.59%

Gross Margin

54.52%

EPS (Latest Qtr)

$0.61

EPS (TTM)

$3.57

Balance Sheet & Liquidity

Debt/Equity

1.08

Quick Ratio

1.80

Current Ratio

3.23

Debt

$2.06B

Total Assets

$4.57B

Current Assets

Working Capital

Ownership

Promoter Holding

1.41%

Chg in Prom Hold

0.01%

FII / Inst Holding

116.33%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$2.48B

Total Revenue (TTM)

$1.10B

EBITDA

$338.20M

Free Cash Flow

$160.61M

Operating Cash Flow

$249.40M

Shares Outstanding

47.37M

Gross Margin

54.52%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PBH Prestige Consumer Healthcare Inc. R2KR3KPHARMA	52.26	14.64	$2.48B	0.00%	9.17%	9.12%	8.56%	11.76%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Jun 2021	Sep 2021	Dec 2021	Jun 2022	Sep 2022	Dec 2022	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Jun 2025	Sep 2025	Dec 2025	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	256.57M	258.03M	270.62M	255.97M	253.98M	239.36M	241.41M	241.03M	232.15M	238.07M	241.55M	251.24M	229.39M	237.42M	238.79M	269.18M	276.23M	274.47M	277.06M	289.27M	275.52M	279.31M	286.32M	282.74M	267.14M	283.79M	290.32M	249.53M	274.11M	283.44M	265.71M
Gross Profit	110.07M	112.24M	119.94M	116.78M	118.25M	121.59M	123.97M	124.55M	130.18M	143.48M	144.10M	147.67M	141.26M	140.62M	137.47M	139.24M	138.25M	134.07M	136.75M	137.50M	143.91M	133.87M	137.66M	138.89M	159.01M	157.71M	155.06M	160.12M	161.01M	150.40M	154.67M	160.02M	157.94M	146.02M	157.38M	161.05M	140.33M	151.58M	157.37M	136.19M
Operating Income	61.24M	62.51M	69.90M	62.64M	65.27M	12.21M	71.06M	69.29M	53.05M	78.95M	75.72M	83.89M	-23.10M	72.49M	70.92M	77.54M	-153.45M	71.49M	69.35M	76.40M	73.92M	80.12M	72.90M	73.44M	91.34M	78.56M	82.59M	87.01M	84.38M	87.18M	85.19M	88.25M	86.83M	72.05M	84.34M	91.96M	71.76M	79.67M	82.49M	52.52M
Net Income	23.77M	26.17M	31.80M	28.00M	13.94M	-5.53M	32.20M	31.64M	11.09M	33.76M	30.70M	314.79M	-39.69M	34.47M	30.84M	38.17M	-139.27M	33.92M	33.25M	38.06M	37.05M	43.71M	44.59M	40.87M	57.76M	45.33M	50.22M	55.27M	51.02M	51.95M	53.28M	53.56M	53.05M	49.07M	54.38M	61.03M	47.47M	42.21M	46.70M	29.18M
Diluted EPS	0.45	0.49	0.60	0.53	0.26	-0.10	0.60	0.59	0.21	0.63	0.57	5.88	-0.75	0.65	0.59	0.73	-2.68	0.65	0.65	0.75	0.73	0.86	0.88	0.81	1.14	0.89	0.99	1.09	1.02	1.04	1.06	1.07	1.06	0.98	1.09	1.22	0.95	0.86	0.97	0.61

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	292.60M	336.51M	441.08M	616.91M	595.64M	713.46M	806.25M	882.06M	1.04B	975.78M	963.01M	943.37M	1.09B	1.13B	1.13B	1.14B	1.09B
Gross Profit	153.44M	170.88M	227.38M	343.74M	335.55M	406.22M	467.21M	500.29M	576.50M	555.58M	552.22M	547.47M	620.65M	625.29M	624.45M	634.46M	595.58M
Operating Income	78.33M	76.14M	102.82M	191.88M	188.62M	207.56M	260.31M	205.64M	215.47M	67.50M	291.15M	297.40M	329.92M	-22.41M	342.43M	336.77M	309.41M
Net Income	32.12M	29.22M	37.21M	65.50M	72.61M	78.26M	99.91M	69.39M	339.57M	-35.80M	142.28M	164.68M	205.38M	-82.31M	209.34M	214.60M	190.30M
Diluted EPS	0.64	0.58	0.73	1.27	1.39	1.49	1.88	1.30	6.34	-0.69	2.78	3.25	4.04	-1.65	4.17	4.29	3.91

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	1.06B	1.76B	1.74B	1.80B	2.64B	2.95B	3.91B	3.76B	3.44B	3.51B	3.43B	3.67B	3.35B	3.32B	3.40B	3.49B
Total Equity	294.38M	329.06M	361.83M	402.73M	477.94M	563.36M	627.62M	744.34M	822.55M	1.18B	1.10B	1.17B	1.36B	1.58B	1.45B	1.66B	1.83B	1.89B
Cash & Equivalents	35.18M	41.10M	13.33M	19.02M	15.67M	28.33M	21.32M	27.23M	41.85M	32.55M	27.53M	94.76M	32.30M	27.18M	58.49M	46.47M	97.88M	63.87M
Long Term Debt	-	-	486.94M	1.12B	970.90M	934.41M	1.56B	1.63B	2.19B	1.99B	1.80B	1.73B	1.48B	1.48B	1.35B	1.13B	992.36M	993.95M
Total Liabilities	-	-	695.09M	1.36B	1.26B	1.23B	2.01B	2.20B	3.09B	2.58B	2.35B	2.34B	2.07B	2.09B	1.91B	1.66B	1.57B	1.61B
Current Liabilities	-	-	54.21M	63.92M	96.67M	84.36M	99.04M	106.68M	162.01M	123.20M	126.98M	149.88M	122.14M	143.42M	160.72M	117.05M	106.62M	120.92M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	59.43M	86.67M	67.45M	137.60M	111.58M	156.25M	176.31M	148.67M	210.11M	189.28M	217.12M	235.61M	259.92M	229.72M	248.93M	251.51M	257.63M
Investing Cash Flow	7.32M	-275.68M	-662.21M	11.22M	-57.98M	-805.26M	-222.97M	-694.60M	-11.56M	55.43M	-16.57M	-22.24M	-256.51M	-11.58M	-20.11M	-17.45M	-136.84M
Financing Cash Flow	-60.83M	161.25M	600.43M	-152.12M	-41.15M	643.26M	52.08M	560.96M	-208.96M	-249.33M	-131.43M	-279.42M	-7.57M	-185.85M	-241.01M	-182.07M	-156.06M
Capital Expenditure	-673.00K	-655.00K	-606.00K	-10.27M	-2.76M	-6.10M	-3.57M	-2.98M	-12.53M	-10.48M	-14.56M	-22.24M	-9.64M	-7.78M	-9.55M	-8.22M	-11.18M
Free Cash Flow	58.75M	86.02M	66.85M	127.34M	108.82M	150.15M	172.74M	145.69M	197.58M	178.80M	202.56M	213.36M	250.28M	221.93M	239.38M	243.29M	246.45M
Share Buybacks	-	-	-	-	-	-	-	0	0	49.98M	56.72M	11.87M	0	50.00M	25.00M	51.51M	156.28M

Ratios (Annual)

Figures in %.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	52.4%	50.8%	51.6%	55.7%	56.3%	56.9%	57.9%	56.7%	55.4%	56.9%	57.3%	58.0%	57.1%	55.4%	55.5%	55.8%	54.7%
Operating Margin %	26.8%	22.6%	23.3%	31.1%	31.7%	29.1%	32.3%	23.3%	20.7%	6.9%	30.2%	31.5%	30.4%	-2.0%	30.4%	29.6%	28.4%
Net Margin %	11.0%	8.7%	8.4%	10.6%	12.2%	11.0%	12.4%	7.9%	32.6%	-3.7%	14.8%	17.5%	18.9%	-7.3%	18.6%	18.9%	17.5%
ROE %	9.8%	8.1%	9.2%	13.7%	12.9%	12.5%	13.4%	8.4%	28.8%	-3.3%	12.2%	12.1%	13.0%	-5.7%	12.6%	11.7%	10.1%
ROCE %	-	7.6%	6.1%	11.7%	11.0%	8.2%	9.2%	5.5%	5.9%	2.0%	8.7%	9.0%	9.4%	-0.7%	10.7%	10.2%	9.2%

Shareholding Pattern

Insiders

1.41%

Institutions

116.33%

Public Float

117.99%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	16.53%	7.83M	$410.91M
2	Ariel Investments, LLC	10.28%	4.87M	$255.46M
3	Vanguard Portfolio Management LLC	5.96%	2.83M	$148.25M
4	Dimensional Fund Advisors LP	5.62%	2.66M	$139.64M
5	Fuller & Thaler Asset Management Inc.	4.92%	2.33M	$122.35M
6	Vanguard Capital Management LLC	4.51%	2.14M	$112.13M
7	State Street Corporation	4.47%	2.12M	$111.05M
8	Brandes Investment Partners L.P.	4.33%	2.05M	$107.62M
9	Kayne Anderson Rudnick Investment Management LLC	3.95%	1.87M	$98.23M
10	Geode Capital Management, LLC	3.32%	1.57M	$82.47M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PBH

Google News Wed, 02 Sep 2026

Is This the Right Time to Add PBH Stock to Your Portfolio? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOQ3UzWHFJelV2M2NpckRIYXlGRU5LQTFDQ1I2SldadU5QNnUxV1ltVnliWm5BSWtPNkp0b2pDOVEzWTUwM2lpUzhZdmFIeEZYZVlvZmpRbTBLMnFGdVJIVmhEQlpLbklRZUN0eUpPbEJLS2Nnak91RDRCaGl6SGZ4QnpLN3hNOThLeUZzak…

Google News Mon, 31 Aug 2026

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Exploring A 29% Upside Potential - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOWGk5MDdHN3kydHpZX2xPUnQ4NTZnSWd2amxYWWlOYkZRbC02dUR2RnZMdG40UVVUazhncGh2YjdPbDRNTFpCVG9tbEwtWUkwWFVrdE5nOUd6QWRLNGtZRVJqbWFxblJpdVl5ckZLb0pteExSRm8yZ2NCWG5VM0pxSEllR1dmUGhEUTVvcl…

Google News ue, 01 Sep 2026

Premium Brands: The Painful Part Might Finally Be Over - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPWXNvQTlib3FVbzhDYWQwdm5XdDFidDFHZThFTXBMeG1OUjRYSUx0NDhmR3FGUEJTSEJiNFVHNGZxVU14RFo4U2FmU05mY0J3VzBjZ3RzTHl4eWwyTmZKbTlBLVI2SUFVUGVzTVZ4UW1NVHN2TGQ0QTlsdlNYWXIyM3FhZ01IcERTOU5lb1…

Google News hu, 27 Aug 2026

Prestige Consumer Healthcare (PBH) Faces An Operations Change, Is The Stock Still Cheap? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOcE9ELUQ1cjRzb1ZyVmZ4VkR1RUN4cTl2RnVQWHJxOHdRYWRyd1BwenNNb1A4aXN3WkxRLXljZktkZ2ZFd09oTGd5X0FzUzlubXRpMnNRMnVmakxiLVVpaDN2THg3OW9aRTVWN29YMUM3Njh3UUJUT3BEbnBzNUxSUERQcUI5ekZfcFFGUG…

Google News Fri, 28 Aug 2026

PBH vs. SYK: Which Stock Is the Better Value Option? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNUXNXNGZxWWp5VXVEQVNQaVFRTlBUWmFwWlRXSGZ2V0RyVExWRVFaMjluTk9NZFFnekpyWmxISXlkaHBBOEFFV2pINjYxTGVEZHZEWjlTbEdEVjdiQWJXM1gwS3JnVjQycmRvWnl2UVJjSjBIemwyb2VDT01QNTlxNW9nMFZVeGNKaElhM0…

Google News Fri, 07 Aug 2026

Prestige Consumer Healthcare Stock (PBH) Opinions on Recent Earnings and M&A Activity - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPaVlwZ2pYbTl1U2R3RlFJT0JCUTMxU0F4eGp0U2VETHp0ZFlYRkpOZm00SUpIODFULVkzWkhGY1F5MmNvYWZ1SVlXUWFWOWIzZnZkcTB1R0R3ZUJRUFgybHFhQ3JFc0lsOGVXUXZGbjRqdXFuRWR5eFhXR2w2bDBqLVZIQjZxR3BlLWpLYn…

PBH — Frequently Asked Questions

What is the current share price of Prestige Consumer Healthcare Inc. (PBH)?

As of 2026-09-07 16:24 PDT, Prestige Consumer Healthcare Inc. (PBH) trades at $52.26 on NYSE. Its 52-week range is $45.44 to $70.21.

What is the market capitalisation of PBH?

Prestige Consumer Healthcare Inc. (PBH) has a market capitalisation of $2.48B on NYSE.

What is the P/E ratio of PBH?

PBH trades at a trailing price-to-earnings (P/E) ratio of 14.64. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.38.

What is the return on equity (ROE) of PBH?

PBH has a return on equity (ROE) of 9.12%. Its return on capital employed (ROCE) is 9.17%.

Is PBH a good stock to buy?

This page provides a data-driven analysis of Prestige Consumer Healthcare Inc. (PBH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Prestige Consumer Healthcare Inc. PBH R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Is This the Right Time to Add PBH Stock to Your Portfolio? - Yahoo Finance

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Exploring A 29% Upside Potential - DirectorsTalk Interviews

Premium Brands: The Painful Part Might Finally Be Over - Seeking Alpha

Prestige Consumer Healthcare (PBH) Faces An Operations Change, Is The Stock Still Cheap? - simplywall.st

PBH vs. SYK: Which Stock Is the Better Value Option? - Yahoo Finance

Prestige Consumer Healthcare Stock (PBH) Opinions on Recent Earnings and M&A Activity - quiverquant.com

PBH — Frequently Asked Questions

What is the current share price of Prestige Consumer Healthcare Inc. (PBH)?

What is the market capitalisation of PBH?

What is the P/E ratio of PBH?

What is the return on equity (ROE) of PBH?

Is PBH a good stock to buy?

Explore More